scholarly journals Genetic Delivery of Bevacizumab to Suppress Vascular Endothelial Growth Factor-Induced High-Permeability Pulmonary Edema

2009 ◽  
Vol 20 (6) ◽  
pp. 598-610 ◽  
Author(s):  
Masaki Watanabe ◽  
Julie L. Boyer ◽  
Ronald G. Crystal
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pulmonary Edema ◽  
Vascular Endothelial ◽  
High Permeability ◽  
Permeability Pulmonary Edema ◽  
Endothelial Growth Factor

Opposing Effects of Isoflurane and Sevoflurane on Neurogenic Pulmonary Edema Development in an Animal Model

2005 ◽  
Vol 102 (6) ◽  
pp. 1182-1189 ◽  
Author(s):  
Nobuhisa Kandatsu ◽  
Yong-Shan Nan ◽  
Guo-Gang Feng ◽  
Kimitoshi Nishiwaki ◽  
Mitsuru Hirokawa ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Animal Model ◽  
Growth Factor ◽  
Pulmonary Edema ◽  
Neurogenic Pulmonary Edema ◽  
Vascular Endothelial ◽  
Lung Water ◽  
Index Of Severity ◽  
Opposing Effects ◽  
Endothelial Growth Factor

Background The current study was undertaken to investigate the effects of pretreatment with isoflurane and sevoflurane on the development of neurogenic pulmonary edema in an animal model. Methods Rats were exposed to room air (control), 1.5% isoflurane, or 2.5% sevoflurane for 4 h. They were then anesthetized with intraperitoneal injections of pentobarbital sodium, and fibrinogen and thrombin were injected into the cisterna magna to induce neurogenic pulmonary edema. Results Consecutive injections of fibrinogen and thrombin caused increases in blood pressure, with the peak values obtained in the isoflurane and sevoflurane groups being lower than the control values. The incidence of significant neurogenic pulmonary edema was 58%, 100%, and 8% in the control, isoflurane, and sevoflurane groups, respectively. The lung water ratio, an index of severity of edema, was 4.86 +/- 0.78, 6.15 +/- 0.64, and 4.40 +/- 0.32 in the control, isoflurane, and sevoflurane groups, respectively. Furthermore, immunohistochemical staining for vascular endothelial growth factor demonstrated an increase of expression in the rat lungs exposed to isoflurane. Treatment with an anti-vascular endothelial growth factor antibody during exposure to isoflurane completely inhibited the effect of isoflurane to promote neurogenic pulmonary edema in this model. Conclusion Exposure to 1.5% isoflurane enhances the development of neurogenic pulmonary edema development in this animal model, most likely via release of vascular endothelial growth factor from bronchial epithelial cells, an effect not observed with sevoflurane.

scholarly journals Lung Overexpression of the Vascular Endothelial Growth Factor Gene Induces Pulmonary Edema

2000 ◽  
Vol 22 (6) ◽  
pp. 657-664 ◽  
Author(s):  
Robert J. Kaner ◽  
John V. Ladetto ◽  
Ravi Singh ◽  
Norimasa Fukuda ◽  
Michael A. Matthay ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pulmonary Edema ◽  
Vascular Endothelial ◽  
Factor Gene ◽  
Growth Factor Gene ◽  
Endothelial Growth Factor

scholarly journals Andes Virus Infection of Lymphatic Endothelial Cells Causes Giant Cell and Enhanced Permeability Responses That Are Rapamycin and Vascular Endothelial Growth Factor C Sensitive

2012 ◽  
Vol 86 (16) ◽  
pp. 8765-8772 ◽  
Author(s):  
Irina N. Gavrilovskaya ◽  
Elena E. Gorbunova ◽  
Erich R. Mackow
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Endothelial Cells ◽  
Growth Factor ◽  
Pulmonary Edema ◽  
Giant Cell ◽  
Giant Cells ◽  
Vascular Endothelial ◽  
Andes Virus ◽  
Factor C ◽  
Endothelial Growth Factor

Hantaviruses primarily infect endothelial cells (ECs) and nonlytically cause vascular changes that result in hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Acute pulmonary edema during HPS may be caused by capillary leakage and failure of lymphatic vessels to clear fluids. Uniquely regulated lymphatic ECs (LECs) control fluid clearance, although roles for lymphatics in hantavirus disease remain undetermined. Here we report that hantaviruses productively infect LECs and that LEC infection by HPS causing Andes virus (ANDV) and HFRS causing Hantaan virus (HTNV) are inhibited by αvβ3integrin antibodies. Although αvβ3integrins regulate permeabilizing responses directed by vascular endothelial growth factor receptor 2 (VEGFR2), we found that only ANDV-infected LECs were hyperpermeabilized by the addition of VEGF-A. However, VEGF-C activation of LEC-specific VEGFR3 receptors blocked ANDV- and VEGF-A-induced LEC permeability. In addition, ∼75% of ANDV-infected LECs became viable mononuclear giant cells, >4 times larger than normal, in response to VEGF-A. Giant cells are associated with constitutive mammalian target of rapamycin (mTOR) activation, and we found that both giant LECs and LEC permeability were sensitive to rapamycin, an mTOR inhibitor, and VEGF-C addition. These findings indicate that ANDV uniquely alters VEGFR2-mTOR signaling responses of LECs, resulting in giant cell and LEC permeability responses. This suggests that ANDV infection alters normal LEC and lymphatic vessel functions which may contribute to edematous fluid accumulation during HPS. Moreover, the ability of VEGF-C and rapamycin to normalize LEC responses suggests a potential therapeutic approach for reducing pulmonary edema and the severity of HPS following ANDV infection.

Vascular endothelial growth factor-C (VEGF-C) overexpression is correlated with poor prognosis in intrahepatic cholangiocarcinoma (CCC)

2001 ◽  
Vol 120 (5) ◽  
pp. A261-A261 ◽  
Author(s):  
Y PAIK ◽  
Y KIM ◽  
S PARK ◽  
J CHUNG ◽  
J CHUNG ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Intrahepatic Cholangiocarcinoma ◽  
Poor Prognosis ◽  
Vascular Endothelial ◽  
Factor C ◽  
Endothelial Growth Factor

361: Serum Levels of Angiogenin and Vascular Endothelial Growth Factor (VEGF) Predict Metastatic Disease in Renal Cell Cancer Patients

2005 ◽  
Vol 173 (4S) ◽  
pp. 99-99 ◽  
Author(s):  
Marcus Horstmann ◽  
Axel S. Merseburger ◽  
Markus A. Kuczyk ◽  
Arnulf Stenzl ◽  
Karl-Horst Bichler ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Cell Cancer ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

359: Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group

2005 ◽  
Vol 173 (4S) ◽  
pp. 98-98
Author(s):  
Richard E. Zigeuner ◽  
Cord Langner ◽  
Peter Rehak ◽  
Marco Auprich ◽  
Katja Lipsky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Serum Levels ◽  
Control Group ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document